Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00186238 · ClinicalTrials.gov registry record · Phase 2
High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma
A Phase 2 study of Multiple Myeloma, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
- 1
- Study location
NCT00186238: Completed Phase 2 study of Multiple Myeloma, sponsored by Stanford University.
NCT00186238 is a Phase 2 study of Multiple Myeloma that has completed, run by Stanford University. The registered enrollment target is 300 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (45% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00186238, a Phase 2 study of Multiple Myeloma, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
To assess the role of autologous hematopoietic cell rescue in the treatment of multiple myeloma.
Conditions Studied
Interventions
- PROCEDURE high dose chemotherapy then autologous hematopoietic cell transplant
Study Locations (1)
California
- Stanford University School of Medicine - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 1994-09 |
| Est. Completion | 2010-04 |
| Phase | Phase 2 |
What the finished NCT00186238 record still lists
NCT00186238 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (45% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which high dose chemotherapy then autologous hematopoietic cell transplant is the first listed.
NCT00186238 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00186238 about?
NCT00186238 is a clinical study titled "High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma". To assess the role of autologous hematopoietic cell rescue in the treatment of multiple myeloma.
What is the current status of trial NCT00186238?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 1994-09. Estimated completion is 2010-04.
What conditions does trial NCT00186238 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT00186238?
The interventions under investigation include: high dose chemotherapy then autologous hematopoietic cell transplant (PROCEDURE).
Who is sponsoring clinical trial NCT00186238?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00186238 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00186238's enrollment target sits among peer trials
300 75th of 438 higher than 361 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia